12:00 AM
Oct 03, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Afluria Quadrivalent: Phase III data

CSL’s Seqirus unit reported data from a double-blind, U.S. Phase III trial in 2,278 children ages 5-17 showing that intramuscular Afluria Quadrivalent met the primary endpoint of non-inferior immunogenicity to Fluarix Quadrivalent as assessed by GMT...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >